Kidney Fibrosis Treatment Market Report 2026

Kidney Fibrosis Treatment Market Overview

• Kidney Fibrosis Treatment market size has reached to $6.06 billion in 2025 • Expected to grow to $8.84 billion in 2030 at a compound annual growth rate (CAGR) of 7.8% • Growth Driver: Rising Prevalence Of chronic kidney disease Driving Growth In The Market Due To Increasing Rates Of Diabetes And Hypertension • Market Trend: Targeted Ileal-Release Immunomodulatory Therapies Drive Treatment Advancements • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Kidney Fibrosis Treatment Market?

Kidney fibrosis treatment refers to therapeutic strategies aimed at slowing, halting, or reversing the progression of fibrosis in the kidneys. Kidney fibrosis is the excessive accumulation of extracellular matrix proteins such as collagen, resulting to scarring and functional decline of kidney tissue, commonly associated with chronic kidney disease (CKD). The main treatment types of kidney fibrosis treatment are angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), pirfenidone, renin inhibitors, vasopeptidase inhibitors, and others. Angiotensin-converting enzyme (ACE) inhibitors help lower blood pressure and reduce heart strain by blocking the enzyme that converts angiotensin I into angiotensin II. Diagnosis involves blood and urine tests, imaging scans, and kidney biopsies. The treatments are applied in cases of chronic kidney diseases, kidney cancer, and other conditions. These are used by various end-users such as clinics, research centers, and hospitals.

What Is The Kidney Fibrosis Treatment Market Growth Forecast?

The kidney fibrosis treatment market size is expected to see strong growth in the next few years. It will grow to $8.84 billion in 2030 at a compound annual growth rate (CAGR) of 7.8%. The growth in the forecast period can be attributed to advancements in targeted antifibrotic agents, increasing aging population with ckd, growing adoption of precision medicine in nephrology, rising investment in renal research, improved early-stage kidney disease diagnosis. Major trends in the forecast period include increasing focus on antifibrotic drug development, growing use of combination therapies for ckd, rising research in stem cell and regenerative therapies, expansion of early diagnostic and monitoring tools, increasing clinical trials targeting renal fibrosis pathways.

Global Kidney Fibrosis Treatment Market Segmentation

1) By Treatment Type: Angiotensin-Converting Enzyme (Ace) Inhibitors, Angiotensin Ii Receptor Blockers (Arbs), Pirfenidone, Renin Inhibitors, Vasopeptidase Inhibitors, Other Treatment Types 2) By Diagnosis: Blood Tests, Urine Tests, Imaging Tests 3) By Application: Chronic Kidney Diseases, Kidney Cancer Treatment, Other Applications 4) By End-User: Clinics, Research Center, Hospitals Subsegments: 1) By Angiotensin-Converting Enzyme (Ace) Inhibitors: Enalapril, Captopri, Lisinopril, Ramipril 2) By Angiotensin Ii Receptor Blockers (Arbs): Losartan, Telmisartan, Valsartan, Irbesartan 3) By Pirfenidone: Branded Pirfenidone, Generic Pirfenidone 4) By Renin Inhibitors: Aliskiren, Experimental Renin Inhibitors 5) By Vasopeptidase Inhibitors: Omapatrilat, Sampatrilat 6) By Other Treatment Types: Anti-Inflammatory Agents, Stem Cell Therapy, Antifibrotic Agents Under Clinical Trials, Gene Therapy

What Is The Driver Of The Kidney Fibrosis Treatment Market?

The increasing prevalence of chronic kidney diseases is expected to propel the growth of the kidney fibrosis treatment market going forward. Chronic kidney disease (CKD) is a gradual loss of kidney function over time, often due to conditions such as diabetes or hypertension, resulting to the accumulation of waste products in the body. The increasing prevalence of chronic kidney disease (CKD) is largely driven by the rising rates of diabetes, which damages kidney blood vessels and impairs their filtering ability. Kidney fibrosis treatment helps chronic kidney disease (CKD) patients by targeting the scarring of kidney tissue, reducing inflammation, and slowing the progression of kidney damage, ultimately preserving kidney function. For instance, in July 2025, according to Hamadan University of Medical Sciences, a Iran-based university, the global number of newly diagnosed chronic kidney diseases is projected to rise to 25.06 million by 2030. Therefore, the increasing prevalence of chronic kidney diseases is driving growth of the kidney fibrosis treatment industry.

Key Players In The Global Kidney Fibrosis Treatment Market

Major companies operating in the kidney fibrosis treatment market are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, AstraZeneca PLC, Gilead Sciences Inc., Novo Nordisk A/S, Boehringer Ingelheim International GmbH, Chinook Therapeutics Inc., Akebia Therapeutics Inc., Travere Therapeutics Inc., Reata Pharmaceuticals Inc., ProKidney LLC, Tvardi Therapeutics Inc., Alentis Therapeutics AG, Galecto Biotech AB, Vertex Pharmaceuticals Incorporated, Insilico Medicine Inc., Purespring Therapeutics Inc., La Jolla Pharmaceutical Company, Cara Therapeutics Inc

Global Kidney Fibrosis Treatment Market Trends and Insights

Major companies operating in the kidney fibrosis treatment market are focusing on targeted ileal-release immunomodulatory therapies, such as NEFECON, an oral delayed-release budesonide capsule that delivers the drug specifically to the distal ileum to modulate gut-associated B-cells and reduce pathogenic IgA production, slowing kidney fibrosis progression in IgA nephropathy patients. For instance, in June 2024, Everest Medicines, a China-based biopharmaceutical company, launched NEFECON. The therapy features an enteric-coated, delayed-release formulation to minimize systemic steroid exposure, targets mucosal B-cells in the gut to address the root cause of IgA nephropathy, and has demonstrated the ability to significantly reduce kidney function decline.

What Are Latest Mergers And Acquisitions In The Kidney Fibrosis Treatment Market?

In April 2025, Novartis, a Switzerland-based pharmaceutical company developing a broad pipeline in renal and rare-disease therapies, acquired Regulus Therapeutics for an undisclosed amount. With this acquisition, Novartis aimed to bolster its kidney-disease franchise by gaining Regulus’s lead RNA-therapeutic candidate, farabursen, a microRNA-17 inhibitor for autosomal dominant polycystic kidney disease (ADPKD), thereby strengthening its pipeline in renal therapies. Regulus Therapeutics is a US-based (San Diego) biopharmaceutical company focused on developing first-in-class microRNA therapeutics, including farabursen for ADPKD.

Regional Insights

North America was the largest region in the kidney fibrosis treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Kidney Fibrosis Treatment Market?

The kidney fibrosis treatment market includes revenues earned by entities by providing services such as pharmacological treatment, diagnostic and monitoring services, and lifestyle and nutritional support. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Kidney Fibrosis Treatment Market Report 2026?

The kidney fibrosis treatment market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the kidney fibrosis treatment industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.